US-based clinical stage biopharmaceutical firm Heat Biologics has announced its plans to begin patient enrolment in its Phase I/II study of HS-410 in bladder cancer.
The Phase I/II bladder cancer trial is designed to determine whether vaccination with HS-410 after transurethral resection of bladder tumour (TURBT) and bacillus Calmette-Guérin (BCG) extends the time to disease recurrence compared to placebo.
Go deeper with GlobalData
The trial will enrol approximately 93 patients and will also test the safety of HS-410 in bladder cancer patients. The company expects to begin dosing patients in this month.
HS-410 is a biologic product candidate designed to activate a T-cell mediated pan-antigen immune response against the patient’s bladder cancer.
HS-410 consists of a bladder cancer cell line that has been genetically modified using Heat’s proprietary immune pan antigen cytotoxic therapy (ImPACT) technology platform.
See Also:
Heat’s ImPACT technology reprograms live cancer cells from a single tumour source to continually secrete gp96, a chaperone protein found in all human cells.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn turn, gp96 chaperones tumour antigens to T-cells to activate a robust, pan-antigen T-cell immune response and direct killer T-cells to attack the patient’s cancer.
Heat’s ImPACT technology holds promise for treating a wide variety of different cancers.
Heat Biologics CEO Jeff Wolf said the company is excited to open enrolment on schedule with its Phase I/II study of HS-410 in patients with bladder cancer.
"This is a significant milestone for the company as we remain focused on advancing Heat’s proprietary ImPACT therapy into late-stage clinical studies," Wolf said.
The company also anticipates HS-410 to represent a feasible opportunity to address a significant unmet medical need since no new medications were approved by the US Food and Drug Administration (FDA) to treat bladder cancer in more than 25 years.
Image: Histopathology of urothelial carcinoma of the urinary bladder. Photo: courtesy of KGH.
